Brawn Biotech Ltd (530207)
🎯 Key Takeaways
- Brawn Biotech Ltd appears to be in a pre-revenue or development-stage phase within the pharmaceuticals sector, with no meaningful revenue generation over the past three fiscal years despite consistent balance sheet growth. The company maintains a debt-free structure and stable promoter holding, but financial performance remains minimal, with alternating periods of zero and nominal profitability.
- Revenue grew 0% QoQ to ₹0 in Q1FY24.
- ⚠️ Persistent zero or negligible revenue over three fiscal years raises concerns about business viability and timeline to commercialization.
📖 The Story
Brawn Biotech Ltd appears to be in a pre-revenue or development-stage phase within the pharmaceuticals sector, with no meaningful revenue generation over the past three fiscal years despite consistent balance sheet growth. The company maintains a debt-free structure and stable promoter holding, but financial performance remains minimal, with alternating periods of zero and nominal profitability. Its narrative is currently centered on capital formation and reserve accumulation rather than operational traction.
📰 What's Happening
Management has not announced any new product launches, regulatory approvals, or strategic partnerships in recent filings. The most notable activity includes a steady increase in reserves from ₹0 to ₹1 crore between FY25 and FY26, suggesting retained earnings or capitalization of expenses. Shareholding data indicates a gradual decline in promoter stake from 53.66% to 52.94% over four quarters, while institutional and DII holdings remain negligible. No major M&A, fundraising, or capital restructuring events have been disclosed in the latest regulatory filings.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2022 | Mar 2023 | Jun 2023 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Operating Profit | 0 | 0 | -0 |
| OPM % | 25.0% | 25.0% | -33.3% |
| Net Profit | 0 | 0 | -0 |
| EPS | ₹0.05 | ₹0.47 | ₹-0.08 |
The company's financial trajectory shows persistent revenue stagnation, with only two quarters of positive operating performance in the past three years — both yielding zero revenue but contrasting profit margins (25% in Mar 2023 and Jun 2022 vs. -33.3% in Jun 2023). This volatility suggests non-recurring or accounting-driven profitability rather than sustainable operations. Net income and EPS remain highly erratic, with a sharp decline from ₹0.47 to ₹-0.08 in consecutive quarters, indicating instability in cost or revenue recognition patterns.
🔮 Management Outlook & What's Next
There is no forward guidance or strategic outlook provided in the latest available filings. Management commentary is absent regarding product development timelines, regulatory milestones, or revenue targets. The lack of operational updates or capital allocation plans suggests either ongoing silence during development phases or insufficient progress to warrant disclosure. Without articulated milestones, future performance remains speculative.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 |
| Reserves | 1 | 0 | 1 | 1 |
| Borrowings | 0 | 0 | 0 | 0 |
| Total Liabilities | 14 | 20 | 22 | 21 |
| Fixed Assets | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 14 | 20 | 22 | 21 |
The balance sheet reflects a conservative capital structure with zero debt and minimal asset growth, primarily driven by incremental reserve accumulation. Equity remains flat at ₹3 crore, while total assets have increased slightly from ₹20 to ₹22 crore, likely reflecting capitalized expenditures or deferred costs. The absence of borrowings and steady asset base suggests the company is self-funding operations through internal resources or shareholder contributions without external leverage.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | +0 |
| Investing | -0 |
| Financing | -0 |
| Net Cash Flow | -0 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 53.7% | 53.4% | 52.9% | 52.9% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% |
| DII | 0.3% | 0.3% | 0.3% | 0.3% |
| Public | 32.9% | 31.0% | 30.5% | 30.5% |
| # Shareholders | 3,958 | 3,444 | 3,303 | 3,284 |
Promoter holding has slightly declined over the past year, from 53.66% to 52.94%, while public shareholding has remained relatively stable. Institutional and DII ownership is minimal and unchanged, indicating limited investor interest or confidence. The stable shareholder base lacks significant movement, but the slight dilution in promoter stake may reflect passive dilution rather than active divestment. No insider selling or activist activity is evident.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.63 L Cr | 38.3 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.43 L Cr | 83.2 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.89 L Cr | 79.1 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.15 L Cr | 34.0 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.00 L Cr | 91.8 | 20.8% | 20.6% | 0.45 |
| LUPIN | 98,305 | 17.4 | 27.9% | 24.7% | 0.26 |
| DRREDDY | 97,741 | 30.3 | 10.1% | 8.4% | 0.17 |
| MANKIND | 97,467 | 47.7 | 13.9% | 12.7% | 0.38 |
| AUROPHARMA | 96,836 | 26.3 | 12.8% | 9.8% | 0.20 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Persistent zero or negligible revenue over three fiscal years raises concerns about business viability and timeline to commercialization. 2. Volatile profitability with negative margins in recent quarters suggests potential issues in cost control or revenue recognition. 3. Absence of forward-looking guidance or product development updates limits transparency on execution risk. 4. Minimal institutional interest and low trading liquidity could exacerbate price volatility on any news.
🧠 Analyst's Read
Brawn Biotech remains in a high-risk, pre-revenue phase with no clear path to operational scale. Investors should monitor for regulatory milestones, new funding announcements, or shifts in capital allocation strategy, as current financials reflect development-stage uncertainty rather than commercial momentum.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd